Tagged with Lundbeck

Italy Tiziana Mele, managing director of Lundbeck Italia, explains the impact of COVID on mental health care from the perspective of a company dedicated to brain health, outlines the Italian operation that includes both  commercial and production capacities and shares Lundbeck’s support of independent clinical trials in the country. At Lundbeck,…

Global 2021 saw PharmaBoardroom’s network of executives and experts weighing in on some of the most pressing issues facing our industry today. See below for five of the most thought-provoking pieces, ranging from patient engagement to access solutions, infrastructure building, biomarkers, and sustainability.   A ‘Bold Vision’ of Patient Engagement The…

Denmark Denmark’s four largest pharma companies – Novo Nordisk, Lundbeck, LEO Pharma, and ALK – are all at least partly owned by independent foundations, which means that their profits are divided between their shareholders and the foundations themselves, with funds then channelled into academia and biotech start-ups. Here, a variety of…

Global With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why the peptide field is generating so much excitement, outline some of the most significant recent breakthroughs and big-ticket investments, and…

India The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its pharma arm, the country’s 15 pharma billionaires, Danish CNS firm Lundbeck’s decision to shutter its Indian operations, Bharat Biotech’s connection to the world’s first malaria vaccine, and the two million missing workers within…

Denmark Since joining Danish neuroscience specialist Lundbeck as its global CEO in 2018, South African Deborah Dunsire has focused on “revitalising and refreshing” the firm’s pipeline, which had seen several failures in the preceding years. In an exclusive recent conversation with PharmaBoardroom, Dunsire explains the strategy she has put in place…

Denmark Speaking exclusively to PharmaBoardroom, Lundbeck’s global CEO Deborah Dunsire describes the progress in the strategy she put in place to “revitalise and refresh” the Danish firm’s pipeline upon taking the role three years ago. Following two recent acquisitions, Lundbeck now has a much broader focus across neuroscience including areas for…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

USA The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their vital role leading operations in the world’s most innovative and lucrative pharma market, translating global cultures to a US reality, and the challenges of attracting and retaining…

USA PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted the long-term damage COVID-19 is causing to the general mental health of society, and how Lundbeck is well-positioned to address this in North America.   As the global pandemic rages on,…

USA Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s specialty portfolio in the US market, the challenges of working in the CNS space, and how the company is adapting to the problems posed by the COVID-19 pandemic.  …

Coronavirus With the global coronavirus pandemic still ongoing and teleworking having become the new normal, pharma executives from across the world are giving us their insights into how they are managing in the age of confinement to ensure continued employee welfare and the safe supply of medications to the patients and…